Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Vext Science's Net Income for the
three
months ended in Mar. 2026 was €-0.77 Mil. Vext Science's Revenue for the
three
months ended in Mar. 2026 was €10.52 Mil. Therefore, Vext Science's net margin for the quarter that ended in Mar. 2026 was -7.34%.
The historical rank and industry rank for Vext Science's Net Margin % or its related term are showing as below:
FRA:VV5'
s Net Margin % Range Over the Past 10 Years
Min: -62.32 Med: 12.63 Max: 30.83
Current: -30
FRA:VV5's Net Margin % is ranked worse than 83.26% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs FRA:VV5: -30.00
Vext Science (FRA:VV5) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vext Science Net Margin % Related Terms
Vext Science Net Margin % Historical Data
* Premium members only.
The historical data trend for Vext Science's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vext Science's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science (FRA:VV5) has a Net Margin % of -7.34% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Vext Science and its competitors. According to the industry distribution chart, Vext Science ranks #801 out of 962 companies in the Drug Manufacturers industry, placing it in the top 83.3%.
Is Vext Science's Net Margin % too high?
Vext Science's current Net Margin % is -7.34%. Based on the distribution chart, Vext Science ranks #801 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vext Science has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #801 out of 962 companies for Net Margin %. This places Vext Science in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current Net Margin % is -7.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current Net Margin % of -7.34%. The stock's GF Value™ is €0.92, compared to a current price of €0.09 — trading 90.5% below its estimated fair value. The current Net Margin % is -7.34%. Vext Science's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current Net Margin % is -7.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.09 is trading 90.5% below its estimated GF Value™ of €0.92.
Key valuation signals for FRA:VV5:
Net Margin %: -7.34%
GF Value™: €0.92 vs. price of €0.09 (90.5% below fair value)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
62GF Score
Get the complete analysis for FRA:VV5
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
